8-K: Century Therapeutics Expands Board with Biotech Veterans

Century Therapeutics strengthens its Board of Directors with the appointment of Dr. Han Lee and Dr. Martin Murphy, bringing extensive financial and life science investment expertise.

Summary

• Century Therapeutics, Inc. increased its Board of Directors from six to eight members.
• Dr. Martin Murphy and Dr. Han Lee were appointed as new directors, effective December 9, 2025.
• Dr. Murphy will serve as a Class III director, with his term expiring at the 2027 Annual Meeting of Stockholders.
• Dr. Lee will serve as a Class II director, with his term expiring at the 2026 Annual Meeting of Stockholders.
• Dr. Murphy will join the Compensation and Nominating and Corporate Governance Committees of the Board.
• Dr. Lee will join the Compensation and Audit Committees of the Board.
• Both new directors received an initial option award to purchase 88,000 shares of common stock, vesting in equal monthly installments over 36 months, and an annual cash retainer of $40,000.
• The Board determined both Dr. Murphy and Dr. Lee are independent directors under applicable Nasdaq listing rules.

Sentiment

Score: 7

Explanation: The appointment of two highly experienced directors with strong backgrounds in finance, corporate development, and life science investment is a positive development for Century Therapeutics, enhancing its strategic capabilities as it advances its pipeline.

Positives

• The addition of two highly experienced biotechnology leaders, Dr. Han Lee and Dr. Martin Murphy, to the Board strengthens strategic oversight.
• Dr. Lee brings extensive capital formation and corporate development leadership experience from various clinical-stage biotechnology companies, including ImmPACT Bio, Neogene Therapeutics, and Arcellx.
• Dr. Murphy brings extensive experience in life science investment, company creation, and strategic oversight from roles as co-founder of Syncona Limited and CEO of Syncona Investment Management Limited, as well as MVM Life Science Partners LLP.
• The new appointments are expected to benefit Century Therapeutics as it advances its iPSC-derived cell therapy programs, including CNTY-813 for type 1 diabetes.
• Strengthens corporate governance and financial oversight with new committee assignments for both directors.

Risks

• Ability to successfully advance current and future product candidates through development activities, preclinical studies, and clinical trials.
• Ability to meet development milestones on anticipated timelines.
• Uncertainties inherent in the results of preliminary data, pre-clinical studies, and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials.
• Ability to obtain clearance of future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all.
• Reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of product candidates.
• The timing, scope, and likelihood of regulatory filings and approvals, including final regulatory approval of product candidates.
• The impact of geopolitical issues, trade disputes and tariffs, banking instability, and inflation on business and operations, supply chain, and labor force.
• The performance of third parties in connection with the development of product candidates, including third parties conducting clinical trials as well as third-party suppliers and manufacturers.
• Ability to successfully commercialize product candidates and develop sales and marketing capabilities, if product candidates are approved.
• Ability to recruit and maintain key members of management.
• Ability to maintain and successfully enforce adequate intellectual property protection.

Future Outlook

The company aims to execute with discipline and focus to bring its most differentiated iPSC-derived cell therapy programs, including CNTY-813 for type 1 diabetes, closer to patients living with high-impact diseases. It anticipates benefiting from the combined expertise and contributions of the new directors as it moves with urgency to bring its lead pipeline candidates into the clinic and deliver significant value for patients and stakeholders.

Management Comments

• "We are pleased to welcome Dr. Lee and Dr. Murphy to our Board at an important time for Century as we execute with discipline and focus to bring our most differentiated iPSC-derived cell therapy programs, including CNTY-813 as a potentially curative, off-the-shelf investigational treatment for type 1 diabetes, closer to patients living with high-impact diseases." Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics.
• "With Dr. Lee's extensive capital formation and corporate development leadership experience and Dr. Murphy's extensive experience in life science investment, company creation and strategic oversight of successfully evolving companies across the public and private sectors, we look forward to benefitting from their combined expertise and contributions as we move with urgency to bring our lead pipeline candidates into the clinic and deliver significant value for patients and stakeholders." Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics.

Industry Context

The appointments reflect a common strategy in the biotechnology sector to strengthen corporate governance and strategic oversight, particularly for clinical-stage companies advancing novel therapies like iPSC-derived cell therapies. Bringing in seasoned executives with financial, corporate development, and investment backgrounds is crucial for navigating capital markets, strategic partnerships, and clinical development challenges inherent in the biotech industry. The company's focus on autoimmune diseases and cancer, and specifically type 1 diabetes with CNTY-813, positions it in highly competitive and innovative therapeutic areas.

Comparison to Industry Standards

• The appointment of directors with deep financial and life science investment backgrounds is standard practice for biotechnology companies, especially those in clinical stages, to enhance strategic decision-making and capital market access.
• Dr. Lee's experience as CFO at multiple clinical-stage biotech companies (ImmPACT Bio, Neogene Therapeutics, Arcellx) and in corporate development at AstraZeneca aligns with the industry's need for strong financial leadership and strategic transaction expertise, as evidenced by ImmPACT Bio's acquisition by Lyell Immunopharma in 2024.
• Dr. Murphy's background as co-founder and CEO of Syncona, a leading UK-based life science investment company, and his roles at MVM Life Science Partners and 3i Group plc, are comparable to top-tier venture capital and private equity professionals often sought for biotech boards, validating his industry relevance through prior board roles at companies like Autolus Therapeutics plc.
• The compensation structure, including stock options and cash retainers, is typical for non-employee directors in publicly traded biotechnology companies, aligning their interests with shareholders.

Management Changes

Corporate Governance

Related Party Transactions

• No transactions in which either of Drs. Murphy or Lee has a direct or indirect material interest requiring disclosure under Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: Potential positive impact due to strengthened board expertise, which could lead to better strategic decisions, improved financial management, and enhanced investor confidence. The option awards align new directors' interests with shareholders.
• Employees: Indirect positive impact from potentially stronger company direction and stability.
• Customers/Patients: Potential positive impact as the company aims to accelerate its pipeline, bringing therapies like CNTY-813 closer to patients.

Next Steps

• Continue to advance iPSC-derived cell therapy programs, including CNTY-813.
• Bring lead pipeline candidates into the clinic.

Key Dates

Recommendation

While the appointments of Dr. Lee and Dr. Murphy are positive developments, bringing valuable financial and strategic expertise to the board, this 8-K filing primarily concerns corporate governance changes rather than direct operational or financial performance updates. The company is still in the clinical-stage, and significant value drivers will be the progress of its pipeline candidates. Therefore, a "hold" recommendation is appropriate, acknowledging the positive governance enhancement without implying immediate significant upside based solely on this announcement. Investors should await further clinical and financial updates.

Keywords

Century Therapeutics, IPSC, Board of Directors, Biotechnology, Cell Therapy, Corporate Governance, Dr. Han Lee, Dr. Martin Murphy, Clinical-stage, iPSC-derived, CNTY-813, Type 1 Diabetes, Autoimmune Diseases, Cancer